Aster DM Healthcare (ASTERDM) Q1 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 24/25 earnings summary
9 Jul, 2026Executive summary
Strategic focus shifted to India after GCC business segregation, positioning for growth in a market with low hospital bed density and rising healthcare demand.
India operations achieved 20% revenue growth to INR 1,002 crore and 39% operating EBITDA growth to INR 177 crore in Q1 FY25.
Net profit post NCI rose 80% to INR 74 crore, driven by operational excellence and investment income; consolidated net profit for the quarter was INR 5,152.20 crores, primarily due to the gain on disposal of the GCC business.
Expansion plans include adding 1,700 beds by FY27, targeting a total of 6,500 beds, with a focus on brownfield projects and selective inorganic growth, especially in South India.
Board approved unaudited financial results for Q1 FY25, with four new directors appointed effective 31 July 2024.
Financial highlights
Revenue grew 20% year-on-year to INR 1,002 crore in Q1 FY25; consolidated revenue from continuing operations was INR 1,001.87 crores.
Operating EBITDA increased 39% year-on-year to INR 177 crore, with margin expanding to 17.7%.
Core hospital and clinic segment revenue up 21% to INR 968 crore; operating EBITDA margin at 20.8%.
ARPOB rose 12% year-on-year to INR 44,200; excluding O&M, ARPOB up 15% to INR 46,800.
Standalone net profit for the quarter was INR 6,008.24 crores, significantly higher due to a one-time gain from the sale of the GCC business.
Outlook and guidance
Blended EBITDA margin expected to rise to 20%-21% in the next 3-4 years, with hospital and clinic segment margins targeted at 23%-24%.
ARPOB growth projected at 7%-8% CAGR over the next 3-4 years, with 3%-3.5% from price increases.
Expansion to focus on brownfield projects and selective inorganic opportunities, especially in South India.
The company completed the separation of its GCC business on 3 April 2024, with the GCC segment now classified as discontinued operations.
A special dividend of INR 118.00 per equity share was distributed following the GCC business sale.
Latest events from Aster DM Healthcare
- Double-digit revenue and profit growth, margin expansion, and strong outlook in H1 FY25.ASTERDM
Q2 24/258 Jul 2026 - Q2 FY26 delivered strong growth, margin expansion, hospital launches, and QCL merger progress.ASTERDM
Q2 25/268 Jul 2026 - Merger forms a top-three Indian hospital chain with 10,150+ beds, strong synergies, and Blackstone backing.ASTERDM
M&A Announcement8 Jul 2026 - 15% YoY revenue and 22% EBITDA growth, merger progress, and internal restructuring marked Q3FY26.ASTERDM
Q3 25/268 Jul 2026 - FY25 revenue up 12%, EBITDA margin at 19.5%, QCIL merger and major one-time gains boost results.ASTERDM
Q4 24/258 Jul 2026 - Aster DM and QCIL merge to form a top 3 Indian hospital chain with 10,150+ beds and strong growth.ASTERDM
Investor Presentation18 Jun 2026 - Strong growth in revenue, capacity, and clinical excellence, with major expansion plans ahead.ASTERDM
Investor Presentation18 Jun 2026 - Merger with QCIL positions the group among India's top 3 hospital chains by scale and revenue.ASTERDM
Investor presentation3 Jun 2026 - Robust revenue and EBITDA growth, with the Quality Care merger and expansion fueling future gains.ASTERDM
Q4 25/261 May 2026